Effect of insulin-unstimulated diabetic therapy with miglitol on serum cystatin C level and its clinical significance

Diabetes Research and Clinical Practice

Volumn 83, Issue 1, 2009, Pages 77-82

  Yokoyama, Hiroki ^a   Inoue, Teruo ^b   Node, Koichi ^b  

^a Jiyugaoka Medical Clinic   (Japan)

^b SAGA UNIVERSITY   (Japan)

Author keywords

Cystatin C; Insulin; Miglitol; Mitiglinide; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; C REACTIVE PROTEIN; CYSTATIN C; INSULIN; MIGLITINIDE; MIGLITOL; UNCLASSIFIED DRUG;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC PATIENT; ENZYME BLOOD LEVEL; FEMALE; HUMAN; INSULIN RELEASE; MALE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE;

1-DEOXYNOJIRIMYCIN; AGED; BENZAMIDES; CYSTATIN C; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED;

EID: 57949096861     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.09.049     Document Type: Article

References (30)

1. Coll E., Botey A., Alvarez L., Poch E., Quinto L., Saurina A., et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am. J. Kidney Dis. 36 (2000) 29-34
2. Fliser D., and Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am. J. Kidney Dis. 37 (2001) 79-83
3. Hoek F.J., Kemperman F.A., and Krediet R.T. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol. Dial. Transplant. 18 (2003) 2024-2031
4. Laterza O.F., Price C.P., and Scott M.G. Cystatin C: an improved estimator of glomerular filtration rate?. Clin. Chem. 48 (2002) 699-707
5. Jernberg T., Lindahl B., James S., Larsson A., Hansson L.O., Wallentin L., et al. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 110 (2004) 2342-2348
6. Koenig W., Twardella D., Brenner H., and Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin. Chem. 51 (2005) 321-327
7. Shlipak M.G., Sarnak M.J., Katz R., Fried L.F., Seliger S.L., Newman A.B., et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N. Engl. J. Med. 352 (2005) 2049-2060
8. Shlipak M.G., Fried L.F., Crump C., Bleyer A.J., Manolio T.A., Tracy R.P., et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107 (2003) 87-92
9. Curhan G. Cystatin C: a marker of renal function or something more?. Clin. Chem. 51 (2005) 293-294
10. Hanefeld M., Fischer S., Julius U., Schulze J., Schwanebeck U., Schmechel H., et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study 11-year follow-up. Diabetologia 39 (1996) 1577-1583
11. DECODE Study Group, European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354 (1999) 617-621
12. Tominaga M., Egichi H., Manaka H., Igarashi K., Kato T., and Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care 22 (1999) 920-924
13. Ceriello A. The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diab. Metab. Res. Rev. 16 (2000) 125-132
14. Ledue T.B., Weiner D.L., Sipe J., Poulin S.E., Collins M.F., and Rifai N. Analytical evaluation of particle-enhanced immunonepherometric assays for C-reactive protein, serum amyloid A, and mannose binding protein in human serum. Ann. Clin. Biochem. 35 (1998) 745-753
15. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
16. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 130 (1999) 461-470
17. Johnston P.S., Lebovitz H.E., Coniff R.F., Simonson D.C., Raskin P., and Munera C.L. Advantages of α-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J. Clin. Endocrinol. Metab. 83 (1998) 1515-1522
18. Malaisse W.J. Pharmacology of the meglitinide analogues. New treatment options for type 2 diabetes mellitus. Treat. Endocrinol. 2 (2003) 401-414
19. Koch M., Beien A., Fusshã Ller A., Zitta S., Haastert B., and Trapp R. Impact of age, body mass index, insulin resistance and proteinuria on the kidney function in obese patients with type 2 diabetes and renal insufficiency. Clin. Nephrol. 69 (2008) 10-17
20. Onat A., Hergenç G., Uyarel H., Ozhan H., Esen A.M., Karabulut A., et al. Association between mild renal dysfunction and insulin resistance or metabolic syndrome in a random nondiabetic population sample. Kidney Blood Press. Res. 30 (2007) 88-96
21. Larsson A., Helmersson J., Hansson L., and Basu S. Serum cystatin C is associated with other cardiovascular risk markers and cardiovascular disease in elderly men. Int. J. Cardiol. 125 (2008) 263-265
22. ter Maaten J.C., Bakker S.J.L., Serne E.H., ter Wee P.M., Donker A.J., and Gans R.O. Insulin acute effects on glomerular filtration rate correlate with insulin sensitivity whereas insulin's acute effects on proximal tubular sodium reabsorption correlate with salt sensitivity in normal subjects. Nephrol. Dial. Transplant. 14 (1999) 2357-2363
23. Halt J.E., Coleman T.G., Mizelle H.L., and Smith Jr. M.J. Chronic hyperinsulinemia and blood pressure regulation. Am. J. Physiol. 258 (1990) F722-F731
24. Shrma A.M., Schoor U., and Distler A. Insulin resistance in young salt-sensitive normotensive subjects. Hypertension 21 (1993) 273-279
25. Sarafidis P.A., and Ruilope L.M. Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. Am. J. Nephrol. 26 (2006) 232-244
26. Yokoyama H., Kanno S., Ishimura I., and Node K. Adiponectin is increased by α-glucosidase inhibitor miglitol-comparison of metabolic profile and atherosclerosis-related markers between miglitol and mitiglinide as an initial therapy for type 2 diabetic patients. Metabolism 56 (2007) 1458-1463
27. Retnakarian R., Cull C.A., Thorne K.I., Adler A.I., Holman R.R., and UKPDS Study Group. Risk factors for renal function in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 55 (2005) 1832-1839
28. Knight E.L., Verhave J.C., Spiegelman D., Hillege H.L., de Zeeuw D., Curhan G.C., et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 65 (2004) 1416-1421
29. Singh D., Whooley M.A., Ix J.H., Ali S., and Shlipak M.G. Association of cystatin C and estimated GFR with inflammatory biomarkers: the Heart and Soul Study. Nephrol. Dial. Transplant. 22 (2007) 1087-1092
30. Arpegard J., Ostergren J., de Faire U., Hansson L.O., and Svenson P. Cystatin C: a marker of peripheral atherosclerotic disease?. Atherosclerosis 199 (2008) 397-401